Genes encoding angiotensin-converting enzymes (Ace and Ace2) are essential for heart function regulation. Cardiac stress enhances Ace, but suppresses Ace2, expression in the heart, leading to a net production of angiotensin II that promotes cardiac hypertrophy and fibrosis. The regulatory mechanism that underlies the Ace2-to-Ace pathological switch, however, is unknown. Here we report that the Brahma-related gene-1 (Brg1) chromatin remodeler and forkhead box M1 (FoxM1) transcription factor cooperate within cardiac (coronary) endothelial cells of pathologically stressed hearts to trigger the Ace2-to-Ace enzyme switch, angiotensin I-to-II conversion, and cardiac hypertrophy. In mice, cardiac stress activates the expression of Brg1 and FoxM1 in endothelial cells. Once activated, Brg1 and FoxM1 form a protein complex on Ace and Ace2 promoters to concurrently activate Ace and repress Ace2, tipping the balance to Ace2 expression with enhanced angiotensin II production, leading to cardiac hypertrophy and fibrosis. Disruption of endothelial Brg1 or FoxM1 or chemical inhibition of FoxM1 abolishes the stress-induced Ace2-to-Ace switch and protects the heart from pathological hypertrophy. In human hypertrophic hearts, BRG1 and FOXM1 expression is also activated in endothelial cells; their expression levels correlate strongly with the ACE/ACE2 ratio, suggesting a conserved mechanism. Our studies demonstrate a molecular interaction of Brg1 and FoxM1 and an endothelial mechanism of modulating Ace/Ace2 ratio for heart failure therapy. 
D
espite modern cardiac care, heart failure remains the leading cause of death, with a mortality rate of ∼50% within 5 y of diagnosis (1) . New mechanisms and therapeutic strategies for heart failure are needed. Most studies focus on the cardiomyocytes' maladaptive response to pathological stress as a cause of heart failure; little is known about how endothelial cells within the heart react to pathological stress to modify heart function. In heart failure patients without coronary artery disease, coronary endothelial dysfunction correlates with adverse cardiac remodeling, contractile abnormalities, and brain natriuretic peptide (BNP) levels (2-6); however, the endothelial function of peripheral arteries is preserved in those patients (3) . These findings suggest that localized endothelial dysfunction in the heart is crucial for cardiac remodeling and hypertrophy. This aspect of cardiac endothelial function, however, is not well understood, and its clinical potential as a therapeutic target has not been sufficiently developed (7) .
Heart function regulation requires angiotensin peptides (8) , which are predominantly produced within the heart. Angiotensin peptides have much higher concentrations in the heart than in the plasma (9) (10) (11) : The interstitial concentration of angiotensin II (Ang II) of the heart is ∼100-fold more than that of plasma (11, 12) . Within the heart, >90% of Ang I is synthesized locally, and >75% of Ang II is produced by enzymatic conversion of the local cardiac Ang I (13, 14) . Cardiac (coronary) endothelial cells are the primary source that produces angiotensin-converting enzymes (Ace and Ace2) to control angiotensin peptide production (8, 15) . Ace and Ace2 are tethered to endothelial cell membrane or secreted into the interstitial space, where these enzymes process Ang I and II peptides. Biochemically, Ace converts the decapeptide Ang I (1-12) to octapeptide Ang II (1-10), whereas Ace2 degrades Ang II to form Ang-(1-7) (16) and cleaves Ang I into Ang-(1-9) (17) . Functionally, Ang II is a potent stimulant of cardiac hypertrophy and fibrosis (8) ; conversely, Ang-(1-7) and Ang-(1-9) inhibit Ang II's cardiac effects to maintain heart function (8, 18) . Therefore, Ace and Ace2 counteract each other to regulate heart function.
When the heart is pathologically stressed, Ace is up-regulated (19) and Ace2 down-regulated (20, 21) , tipping the balance to Ace dominance with enhanced Ang II and reduced Ang-(1-7) and -(1-9) production. Such Ace/Ace2 perturbation contributes to the development of hypertrophy and heart failure. Inhibition of Ace (22) or overexpression of Ace2 protects the heart from stress-induced failure (20) ; conversely, Ace2 knockout mice exhibit heart dysfunction (23) . Therefore, Ace promotes cardiac pathology (22) , whereas Ace2 inhibits cardiomyopathy (20, 23) . Balancing Ace/Ace2 is thus critical for maintaining heart function.
Significance
Angiotensin-converting enzymes Ace and Ace2 counteract each other to control the metabolism of angiotensin peptides and heart function. When the heart is pathologically stressed, Ace is up-regulated whereas Ace2 is down-regulated, leading to a pathological Ace2-to-Ace switch and increased production of angiotensin II, which promotes hypertrophy and fibrosis. The mechanism of Ace2-to-Ace switch is unknown. In this study, we discovered that the Ace/Ace2 switch occurs at the transcription level and defined a chromatin-based endothelial mechanism that triggers Ace/Ace2 transcription switch and heart failure. Human tissue studies suggest that this mechanism is evolutionarily conserved. Our studies reveal a pharmacological method to simultaneously inhibit pathogenic Ace and activate cardioprotective Ace2. This finding provides new insights and methods for heart failure therapy.
It is unclear how Ace and Ace2 expression is controlled by endothelial cells within the heart. Gene regulation requires control at the level of chromatin, which provides a dynamic scaffold to package DNA and dictates accessibility of DNA sequence to transcription factors. Here we show that Brahma-related gene-1 (Brg1), an essential ATPase subunit of the BAF chromatinremodeling complex (24) , is activated by pathological stress within the endothelium of mouse hearts to control Ace and Ace2 expression. Brg1 complexes with the forkhead box transcription factor forkhead box M1 (FoxM1), which has both transactivating and repressor domains for transcription regulation, to bind to Ace and Ace2 promoters to simultaneously activate Ace and repress Ace2 transcription. Mice with endothelial Brg1 deletion or with FoxM1 inhibition or genetic disruption show resistance to stressinduced Ace/Ace2 switch, cardiac hypertrophy, and heart dysfunction. In human hypertrophic hearts, BRG1 and FOXM1 are also highly activated, and their activation correlates strongly with the ACE/ACE2 ratio and disease severity, indicating a conserved endothelial mechanism for human cardiomyopathy. Brg1 and FoxM1 are therefore essential endothelial mediators of cardiac stress that triggers pathological hypertrophy. Given the lack of ACE2 drugs that limit full clinical exploitation of this pathway, targeting the Brg1-FoxM1 complex may offer an alternative strategy for concurrent ACE and ACE2 control in heart failure therapy. Furthermore, the studies demonstrated a molecular interaction between Brg1 and FoxM1 in gene control, which provides novel insights into the mechanisms of FoxM1-mediated organ development and oncogenic processes (25) (26) (27) .
Results

Dynamic Changes of Endothelial Factors that Contribute to Cardiac
Hypertrophy. To identify endothelial factors that might contribute to cardiomyopathy, we surveyed a number of endothelial genes for their changes of expression after left ventricular pressure overload generated by transaortic constriction (TAC) (24, 28) . TAC-induced heart dysfunction was verified by echocardiography and molecular markers Myh6, Myh7, Anf, Bnp, and Serca2a (Figs. S1 A and B and S2 A-D). By performing reverse transcription and quantitative PCR (RT-qPCR) of left ventricles (LVs), we examined the expression of the following cardiac endothelial factors with or without TAC: eNos, Et-1, Adamts1, Hdac7, Nrg1, Ace, and Ace2 (29). Within 7 d after TAC, Et-1 and Ace were induced 2.0-and 2.1-fold in LVs, whereas Enos and Ace2 were reduced by 46% and 43%, respectively (Fig. 1A) . Adamts1, Hdac7, and Nrg1 had no significant changes.
Given that Ace and Ace2 encode enzymes that are critical for heart function (20) (21) (22) (23) 29) , we focused on the control of Ace and Ace2 expression in TAC-stressed hearts. Immunostaining showed that Ace proteins were present at low levels in healthy hearts, but up-regulated in the endothelium of stressed hearts ( Fig. 1 B and C and Fig. S1 C and D) . In contrast, Ace2 proteins were present at high levels in the endothelium of healthy hearts, but down-regulated in TAC-stressed hearts ( Fig. 1 D and E) . To further verify the opposite changes of Ace and Ace2 in endothelial cells, we used anti-CD31 magnetic beads to isolate endothelial cells from hearts after 7 d of sham or TAC operation (30) (Fig. S1 E and F) . Immunostaining with anti-CD31/Pecam showed that endothelial cells constituted >90% of the sorted cells ( Fig. S1 E and F) . Western blot analysis confirmed that Ace proteins were up-regulated to 2.0-fold and Ace2 proteins reduced by 46%, with the ratio of Ace/Ace2 proteins changed by 3.7-fold in endothelial cells of the stressed hearts ( Fig. 1 H and I) . Such Ace and Ace2 misregulation was also present after 2 and 4 wk of TAC (Fig. S2) .
With the view that Ace is known to promote cardiac pathology (22) , whereas Ace2 inhibits cardiomyopathy (20, 23) , such opposite expression dynamics indicates that a loss of balance between Ace and Ace2 in pressure-stressed hearts is crucial for the development of pathological hypertrophy. Furthermore, the magnitude of stress-induced changes in Ace and Ace2 proteins was comparable to that of mRNA ( Fig. 1 A and I) , indicating that the primary regulation of Ace and Ace2 in stressed hearts occurs at the transcription level.
Endothelial Brg1 Is Essential for Cardiac Hypertrophy and Dysfunction.
Given that gene-transcription control requires chromatin regulation and that the chromatin remodeler Brg1 is known to control the pathological Myh6/Myh7 switch in stressed cardiomyocytes (24, 28) , we hypothesized that Brg1, like in the control of the Myh6/ Myh7 switch, could function in endothelial cells to control the Ace/ Ace2 switch in stressed hearts. Immunostaining showed that Brg1 was expressed at a minimal/low level in endothelial cells of healthy adult hearts. However, when the hearts were stressed by TAC, Brg1 was up-regulated in the nuclei of both cardiomyocytes and endothelial cells ( Fig. 1 G and I) . To compare Brg1 expression in cardiomyocytes and endothelial cells, we isolated these two types of cells from sham or TAC-stressed hearts (30) (Figs. S1 E and F and S3A). We found comparable changes of Brg1 expression in those two cell types. TAC increased Brg1 mRNA by ∼1.6-fold and Brg1 protein by twofold in both cardiomyocytes and endothelial cells (Fig. S3 B-D) . Although Brg1 activation in cardiomyocytes is crucial for the development of cardiac hypertrophy (24, 28) , the function of Brg1 in the endothelium of hypertrophic hearts was unknown.
To test the role of endothelial Brg1 in stressed hearts, we used a tamoxifen-inducible SclCre ERT mouse line (31) sufficient to activate a β-galactosidase reporter (R26R) and to disrupt Brg1 expression in endothelial cells, but not cardiomyocytes, of TAC-stressed hearts ( Fig. 2 A-D fl/fl mice lacking endothelial Brg1 (Fig. 2E) . Analysis of the cardiac mass (ventricle-body weight ratio) showed an ∼50% reduction of hypertrophy (from 77% to 41%) in SclCre ERT ;Brg1 fl/fl mice (Fig. 2F ). Cell size measurement by wheat germ agglutinin (WGA) staining revealed ∼70% reduction of cardiomyocyte size (from 74% to 21%) in SclCre ERT ;Brg1 fl/fl mice ( Fig. 2G and Fig. S4 B-E). There was also a dramatic reduction of interstitial fibrosis in the SclCre To further determine cardiac function, we inserted a catheter from the right carotid artery retrograde into the LV to measure its pressure and volume (Fig. 2K) . The in vivo catheterization showed that TAC increased the peak LV systolic pressure from 100 to 150 mmHg ( Fig. 2K) , with a peak pressure overload of ∼50 mmHg. This LV pressure overload was comparable between the control and mutant hearts (Fig. 2L ). The peripheral systolic pressure (right carotid artery) was identical to that of LV and had no difference between control and mutant mice. Endothelial Brg1 deletion greatly improved the function of TAC-stressed hearts. SclCre ERT ; Brg1 fl/fl mice exhibited much better cardiac function 4 wk after TAC. Ejection fraction (EF) improved by 49% (P < 0.001) (Fig.  2M) ; preload-adjusted maximal power (plPwr) by 38% (P = 0.04) (Fig. 2N) ; stroke volume (SV) by 35% (P = 0.02) (Fig. 2O) ; and stroke work (SW) by 20% (P = 0.03) ( fl/fl mice, molecular markers Myh6 and Serca2a were significantly increased, whereas the stress markers Myh7, Anf, and Bnp were much reduced (Fig. S4F ). This result is consistent with the resistance of SclCre ERT ;Brg1 fl/fl to TAC-induced heart failure. Overall, endothelial Brg1-null mice had a 50-70% reduction of cardiac hypertrophy, minimal/absent interstitial fibrosis, and reduction of heart functional decline after TAC. These findings indicate that the Brg1 is activated by stress in cardiac endothelial cells to trigger hypertrophy.
Endothelial Brg1 Controls Ace/Ace2 Expression and Ang I/II Metabolism.
Given that defective angiogenesis might contribute to cardiac hypertrophy and failure (33), we examined cardiac vessel density to test whether endothelial Brg1 was essential for angiogenesis in stressed hearts. By Pecam staining, we found no difference in vascular density of control and SclCre ERT ;Brg1 fl/fl hearts treated with tamoxifen and TAC ( Fig. S5 A-E).
We then tested whether endothelial Brg1 controlled changes of Ace and Ace2 in stressed hearts. By RT-qPCR of heart ventricles, we examined the expression of eNos, Et1, Adamts1, Hdac7, Nrg1, Ace, and Ace2 in tamoxifen-treated control and SclCre ERT ;Brg1 fl/fl hearts with or without TAC. Among these genes and after TAC, the stress-induced opposite changes of Ace and Ace2 were evident in the control mice, with TAC increasing Ace/Ace2 ratio by 4.3-fold (Fig. 3A) . However, such Ace/Ace2 changes were eliminated in the TAC-stressed hearts of SclCre ERT ;Brg1 fl/fl mice ( Fig.  3A and Fig. S5 F and G) , indicating that endothelial Brg1 is essential for Ace up-regulation and Ace2 down-regulation in stressed hearts. In contrast, the changes of other endothelial genes (eNos, Et1, Adamts1, Hdac7, and Nrg1) were not affected by endothelial Brg1 (Fig. S5H) . These data suggest a degree of Brg1 specificity in control of the Ace/Ace2 switch. Consistently, immunostaining showed that Brg1 was required for the pathological switch of Ace and Ace2 proteins in the heart endothelium. TAC-induced Ace protein up-regulation and Ace2 down-regulation were essentially abolished in the SclCre ERT ;Brg1 fl/fl hearts (Fig. 3 B-I ). These findings were confirmed by Western blot quantitation of Ace and Ace2 in heart protein extracts from the control and mutant mice (Fig. 3 J and K) . Furthermore, consistent with the Brg1-mediated control of the Ace/Ace2 ratio, the TAC-induced Ang I reduction (Fig. 3L) . Also, despite the cardiac changes of angiotensin, Brg1 mutation caused no change of Ang II in the plasma (Fig. 3M) . These findings are consistent with cardiac Ang I and II being primarily produced locally (11) (12) (13) (14) and that such local angiotensin production is regulated by cardiac endothelial Brg1. Collectively, the results indicate that endothelial Brg1 responds to cardiac stress to activate Ace and repress Ace2 expression, triggering a pathological switch of Ace and Ace2 in stressed hearts. (Fig. 3N) . Chromatin immunoprecipitation (ChIP) assay using anti-Brg1 antibody (34) showed that, in TAC-operated hearts Brg1 was highly enriched in three of a1-a4 regions (a2, a3, and a4), compared with the sham-operated hearts (Fig. 3O) . Additionally, we analyzed the 5.5-kb upstream region of the mouse Ace2 promoter, which contained five highly conserved regions among different species (b1-b5 in Fig. 3P ). ChIP analysis of the TAC-stressed heart ventricles showed that Brg1 was highly enriched in three of the b1-b5 regions (b2, b3, and b4), compared with the shamoperated hearts (Fig. 3Q) . These ChIP studies of stressed hearts indicate that Brg1, once activated by stress, binds to evolutionarily conserved regions of Ace and Ace2 proximal promoters.
Brg1 Binds to the Promoters of
We next tested the transcriptional activity of Brg1 on Ace and Ace2 promoters. We cloned Ace upstream promoter (−2,983 to +174 bp) and Ace2 upstream promoter (−7,063 to +786 bp) into the episomal reporter pREP4 that allows promoter chromatinization in mammalian cells (24, 35) . We then transfected the reporter and Brg1-expressing plasmids into mouse cardiac (coronary) endothelial cells for reporter assays (36) . In these cells Brg1 caused 1.7-fold increase in Ace promoter activity and 59% reduction in Ace2 promoter activity (Fig. 3R) . These reporter studies, combined with the ChIP results, indicate that Brg1 activates the Ace promoter and represses the Ace2 promoter. This finding provides a molecular explanation for the antithetical changes of Ace and Ace2 in stressed hearts.
Endothelial FoxM1 Is Required for Stress-Induced Cardiac Hypertrophy
and Pathological Ace/Ace2 Switch. We next hypothesized that FoxM1 (a forkhead box transcription factor) was the transcription factor that worked with Brg1 to antithetically regulate Ace and Ace2 expression and contribute to cardiac hypertrophy. This hypothesis was based on the following observations. First, FoxM1 regulates the expression of genes associated with pathological hypertrophy (37, 38) . Second, the FoxM1 protein contains both transactivation and repressor domains, capable of functioning as a transcription activator or repressor (25) (26) (27) . Third, we found that FoxM1 had expression dynamics in fetal, normal adult, and stressed adult hearts, similar to that of Brg1. RT-qPCR and immunostaining of heart ventricles showed that FoxM1 was abundant in fetal hearts (Fig. S6A ), but its expression was downregulated in normal adult hearts. In contrast, in TAC-stressed hearts, FoxM1 mRNA increased by 8.4-fold (Fig. 4A) , and the proteins were up-regulated in the nuclei of both cardiomyocytes and endothelial cells of stressed hearts (Fig. 4 B and C and Fig. S6  B and C) . Western blot analysis of isolated cardiac endothelial cells and cardiomyocytes showed that FoxM1 protein was upregulated by 2.5-and 2.3-fold after stress (Fig. 4 D and E and Fig.  S6 D and E) .
We then tested the necessity of FoxM1 activation for cardiac hypertrophy by using the FoxM1 inhibitor thiostrepton (39, 40) in TAC-stressed hearts. Within 4 wk after TAC, the control mice injected with the vehicle (DMSO) developed severe cardiac hypertrophy with increased ventricle-body weight ratio, interstitial fibrosis, and cardiac dysfunction with reduced left ventricular FS (Fig. 4 F-I) . In contrast, thiostrepton-treated mice exhibited mild cardiac hypertrophy (Fig. 4F) , mild interstitial fibrosis (Fig. 4 G  and H) , and a lesser degree of cardiac dysfunction (Fig. 4I ). There was a ∼50% reduction of hypertrophy and 28% improvement of FS, comparable to the improvement observed in endothelial Brg1-null hearts (Fig. 2 F and J) . In addition, Western blot analysis of heart ventricles showed that TAC-induced Ace and Ace2 switches were abolished when FoxM1 was inhibited by thiostrepton, with the Ace/Ace2 ratio reduced by 6.5-fold in stressed hearts (Fig. 4 J  and K) . This finding suggests that FoxM1 is required for the pathological switch of Ace and Ace2.
To test the genetic role of FoxM1 in endothelial cells, we crossed SclCre ERT mice (31) with mice that carried floxed FoxM1 alleles (41) hearts, FoxM1 protein was absent in endothelial cells, but not in cardiomyocytes (Fig. 4 L and M) , indicating an endothelial knockout of FoxM1. Within four weeks after TAC, SclCre ERT ;FoxM1 fl/fl mice displayed ∼50% reduction of cardiac mass (ventricular/body weight ratio reduced from 68% to 36%, P < 0.01) (Fig. 4N ) and ∼55% reduction of cardiomyocyte size measured by WGA staining (from 69% to 31%, P < 0.01) (Fig. S6 F-J) . Also, SclCre showed ∼50% improvement of left ventricular FS by echocardiography (P = 0.02) (Fig. 4O) and a dramatic reduction of stressinduced interstitial fibrosis (Fig. 4 P and Q) . A complete characterization of heart function by cardiac catheterization further validated that endothelial FoxM1 deletion greatly improved the function of TAC-stressed hearts (Fig. 4R) . Endothelial FoxM1 deletion improved EF of the stressed hearts by 49%, SV by 32%, CO by 28%, and plPwr by 54% (Fig. S7 A-D) . The left ventricular ESV was reduced by 32% (P < 0.01), and end-diastolic volume was reduced by 11% (P = 0.03). The stress-induced changes of diastolic relaxation (Tau) were reduced by 34% (Fig. S7 E-G) , and the left ventricular filling pressure (EDP) was reduced by 38% (P < 0.01) (Fig. S7H) . These findings indicate that endothelial FoxM1 disruption prevents the development of cardiac dysfunction in stressed hearts. Furthermore, the TAC-induced pathological Ace/Ace2 switch was abolished with Ace/Ace2 ratio normalized in those hearts lacking endothelial FoxM1 (Fig. 4S) . These findings indicate that activation of endothelial FoxM1 expression is essential for stress-induced cardiac hypertrophy and the pathological Ace/Ace2 switch.
Brg1 Cooperates with FoxM1 in the Endothelium to Control Cardiac
Ace and Ace2 Expression. Given that both FoxM1 and Brg1 could regulate Ace/Ace2 switch in stressed cardiac endothelium, we tested whether there was a direct physical interaction between these two proteins. We found that Brg1 coimmunoprecipitated with FoxM1 in stressed heart ventricles (Fig. 5A) . Proximity ligation (Duolink) assay (42, 43) further confirmed that Brg1 and FoxM1 formed a protein complex in the nuclei of mouse cardiac endothelial cells (Fig. 5 B and C) . We then asked whether FoxM1, like Brg1, could bind to the promoters of Ace and Ace2 in stressed hearts. ChIP analysis showed that FoxM1 was highly enriched in the conserved regions of Ace and Ace2 proximal promoters of TAC-stressed hearts relative to the sham-operated hearts (Fig. 5  D and E) . The binding pattern of FoxM1 was broadly similar to that of Brg1 (Fig. 3 M and O) . Given that DNA elements could be looped and brought together by proteins bound to them and that Brg1 and FoxM1 formed a physical complex in stressed endothelial cells, the results suggest that Brg1 and FoxM1 form a protein complex on Ace and Ace2 promoters to orchestrate regulatory DNA elements to control Ace and Ace2 expression. Furthermore, luciferase reporter assays conducted in mouse cardiac endothelial cells showed that FoxM1, like Brg1, was capable of activating Ace and repressing Ace2 promoter activities (Fig. 5 F  and G) . Inhibition of FoxM1 by thiostrepton (39, 40) eliminated Brg1-mediated Ace promoter activation and Ace2 promoter repression (Fig. 5 F and G) . Likewise, knockdown of Brg1 abolished FoxM1's activity on Ace activation and Ace2 repression ( Normal LVH n=7 n=4
Normal LVH n=7 n=4
Normal LVH n=7 n=4 Fig. 5H ). Without the transactivation domain, the FoxM1-ΔTAD mutants failed to activate the Ace promoter, but maintained its repression of the Ace2 promoter (Fig. 5 I and J) . Conversely, without the repressor domain, FoxM1-ΔNRD mutants failed to repress the Ace2 promoter, but preserved effects on Ace promoter activation ( Fig. 5 I  and J) . These results indicate that FoxM1 functions through different transcriptional effector domains for the regulation of Ace and Ace2 promoters, providing a molecular explanation for the antithetical effects of the Brg1-FoxM1 complex on Ace and Ace2. Overall, the ChIP and reporter analyses, combined with the stressinduced formation of the Brg1-FoxM1 complex, suggest that Brg1 and FoxM1 cooperate to regulate the pathological switch of Ace and Ace2 in the stressed heart.
Implications for Human Cardiac Hypertrophy. To investigate whether BRG1 and FOXM1 were also activated in the endothelial cells of human hypertrophic hearts, we studied patients with left ventricular hypertrophy (LVH). The tissue samples were obtained from donor hearts that were considered unsuitable for transplantation because of the lack of timely recipients or mismatched surgical cut (Fig. S8) . RT-qPCR of mRNA showed that the human hypertrophic hearts had a 2.1-and 2.6-fold increase of FOXM1 and BRG1, a 3.4-fold increase of ACE, and a 51% reduction of ACE2, with the ACE/ACE2 ratio increased by 6.7-fold (Fig. 6A) . Like in mice, BRG1 and FOXM1 were up-regulated in both cardiomyocytes and endothelial cells of the hypertrophic hearts ( Fig.  6 B-E). Nonlinear regression analysis showed that the level of BRG1 and FOXM1 correlated strongly with the level of pathological switch of ACE/ACE2 in human hearts ( Fig. 6F ; r 2 = 0.848 and 0.995, respectively). The human tissue studies thus suggest an evolutionarily conserved mechanism underlying myopathy of mouse and human hearts.
Discussion
Controlling Ace/Ace2 expression is critical for maintaining cardiac function, given that an increase of Ace or reduction of Ace2 is sufficient to cause cardiomyopathy (20, 23, 46) . We showed that the Ace and Ace2 amount in the heart is controlled primarily at the transcription level and identified an endothelial chromatin complex composed of Brg1 and FoxM1 that transcriptionally activates Ace and represses Ace2 in response to cardiac stress (Fig. 6G) . This finding provides new molecular insights into endothelial-myocardial interaction under pathological conditions. The requirement of the Brg1-FoxM1 complex for pathological hypertrophy has important implications for heart failure therapy. In stressed hearts, a chemical inhibitor of FoxM1 is effective in reversing Ace/Ace2 and preventing cardiac hypertrophy and dysfunction. It is therefore pharmacologically feasible to inhibit Ace and activate Ace2 simultaneously to improve heart function. Given that there has not been an effective chemical activator of Ace2, likely because of the difficulty of generating protein activators of any kind, chemical inhibition of Brg1-FoxM1 complex reveals a new avenue for pharmacologically targeting Ace and Ace2 genes simultaneously to reverse Ace/Ace2 ratio in failing hearts. Besides Ace/Ace2 regulation, broader functions of the endothelial Brg1-FoxM1 complex will require a future genome-wide approach to determine other downstream targets of this complex in stressed hearts.
At the molecular level, Brg1 and FoxM1 interactions show a molecular mechanism for Brg1 and FoxM1 in gene regulation. The FoxM1 protein contains both a transactivating and a repressor domain for transcription regulation. How such dual transcription activity of FoxM1 is controlled remains unclear. We showed here that Brg1 is essential for FoxM1 to repress Ace and to activate Ace2. However, it remains unknown how Brg1 enables FoxM1 to use its repressor domain on one promoter (such as Ace) and its transactivating domain on another promoter (such as Ace2). Such promoter-specific activity of FoxM1 may be caused by how Brg1 rearranges the chromatin-DNA for FoxM1 to bind or by other unidentified factors in the promoter that differentially expose or enable the FoxM1 transactivating or repressor domain. Given that FoxM1 is required for embryogenesis and is a protooncogene up-regulated in many human cancers, including lung, breast, and colon cancers (25) (26) (27) 47) , future studies to define the molecular details of the differential domain use of FoxM1 may have important implications in organ development, cardiac hypertrophy, and many other diseases.
Materials and Methods
Brg1
fl/fl , FoxM1 fl/fl , and SclCre ERT [endothelial-SCL-Cre-ERT (31)] mice have been described (32, (48) (49) (50) . Littermate CD1 male mice were purchased from Charles River (strain code 022). Animal use protocol was reviewed and approved by Indiana University Institutional Animal Care and Use Committee (IACUC). 
